期刊文献+

顺铂植入剂经皮肝植入治疗肝癌的药动学研究 被引量:3

Pharmacokinetics of Cisplatin Implants with Percutaneous Liver Insertion in the Liver Cancer Therapy
原文传递
导出
摘要 目的探讨顺铂植入剂在肝癌患者肿瘤部位植入后的药动学规律。方法 B超引导下,用穿刺器械在肝癌患者瘤内多点穿刺植药;采集静脉血,石墨炉原子吸收法测定,测定结果进行加权处理、药动学模型拟合。结果顺铂植入剂在体内的过程为一室缓释模型,药动学方程是:ρt=A1e-Ket+A2e-Kat+A3e-Krt,血药达峰时间及峰浓度分别为110h及0.35mg·mL-1,吸收、消除半衰期分别为2及300h。结论此种给药方法的全身血循环药动学特点和参数,可为临床合理应用顺铂植入剂进行肝癌瘤内局部植入的间质化疗提供参考依据。 OBJECTIVE To demonstrate pharmacokinetic properties of cisplatin implants in patients receiving percutaneous liver implantation for treating hepatocellular carcinoma.METHODS Under ultrasound-guided,multiple needle punctures were made and the insertion of cisplantin implants performed in the tumor.Venous blood samples with different intervals were collected accordingly.The samples were determined with graphite furnace atomic absorption spectrometry,and the obtained data were processed and described with the pharmacokinetic model.RESULTS The in vivo course of cisplatin implants was expressed as the one compartment model.The main pharmacokinetic parameters were as follows:ρt =A1e-Ke t+A2e-Ka t+A3 e-Kr t.The peak time tmax and corresponding peak concentration ρmax of cisplatin were 110 h and 0.35 mg·L-1,respectively.The absorption half-life was 2 h,and the elimination half-life was 300 h.CONCLUSION This study results provide pharmacokinetic profile for the percutaneous liver insertion of cisplatin implants clinically for the interstitial chemotherapy.
出处 《中国药学杂志》 CAS CSCD 北大核心 2010年第22期1753-1757,共5页 Chinese Pharmaceutical Journal
基金 安徽省十一五科技攻关重点项目(06013062A) 安徽省教育厅自然科学重点项目(KJ2007135AZC)
关键词 顺铂 植入剂 原发性肝癌 经皮肝植入 石墨炉原子吸收法 药动学 cisplatin implants hepatocellular carcinoma percutaneous liver insertion GF-AAS pharmacokinetics
  • 相关文献

参考文献15

  • 1BARABAS K, MILNER R, LURIE D,et al. Cisplatin: a review of toxicities and therapeutic applications [ J]. Vet Comp Oncol, 2008,6(1 ) : 1-18.
  • 2YAPP D T, LLOYD D K, ZHU J. Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or ip injection in tumor-bearing mice[J]. Anticancer Drugs, 1998,9 (9) : 791-796.
  • 3GE Y Q ZHANG Y Q Lu G C et al.Simultaneous determination of cisplatin and etoposide in plasma and tissue by HPLC.药物分析杂志,2003,23(2):87-90.
  • 4GRYPARIS E C, HATZIAPOSTOLOU M, PAPADIMITRIOU E. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer ceils [ J ]. Eur J Pharm Biopharm, 2007,67(1) : 1-8.
  • 5SUN Y, SHI Y K. Clinical Manual for Internal Medicine( 内科医学临床手册) [M]. 5^thed. Beijing: People's Medical Publishing House, 2008: 10-11.
  • 6FENG M,AN H J. Interstitial chemotherapy for liver,gall-bladder and pancreatic carcinomas. In Li Y,New technique of the microinvasive treatments against the liver, gall-bladder and pancreatic carcinomas(肝癌、胆囊和胰腺癌的微创治疗新技术) [ M]. Beijing: Beijing Science and Technology Press, 2009:211-241.
  • 7KIM J H ,KIM Y S ,PARK K. Antitumor efficacy of cisplatinloaded glycol chitosan nanoparticles in tumor-bearing mice [ J ]. J Controlled Release, 2008,127 : 4149.
  • 8BIASINO J,DOM NGUEZ J R,ALVARADO J. Hydrogen peroxide in basic media for whole blood sample dissolution for determination of its lead content by electrothermal atomization atomic absorption spectrometry [ J ]. Talanta, 2007,73 (5) : 962-964.
  • 9RAGHAVAN R,MULLIGAN J A. Low-level (PPB) determination of cisplatin in cleaning validation ( rinse water) samples. I. An atomic absorption spectrophotometric method [ J ]. Drug Dev Ind Pharm,2000 ,26( 4 ) : 423-428.
  • 10IUPAC. Nomenclature,symbols, units and their usage in spectrochemical analysis - IlL Analytical flame spectroscopy and associated non-flame procedures[ J ]. Pure Appl Chem, 1976,45 ( 2 ) : 106-122.

二级参考文献22

  • 1谢鸿寿,许健健,李永安,孙昕,许道群,任翠萍,陆克亮,吕觉多.T引导下经皮穿刺缓释顺铂瘤体内植入治疗非小细胞肺癌[J].第四军医大学学报,2005,26(1):95-96. 被引量:5
  • 2王世亮,陈殿良,丁满志,储成顶,叶红杨,周丽春,吴静,王军.顺铂植入剂兔舌内植入药动学研究[J].安徽医药,2007,11(6):487-489. 被引量:5
  • 3姜启源.数学模型[M].北京:高等教育出版社,1999..
  • 4赵庆春.原子吸收分光光度法测定顺铂尿药浓度[J].沈阳部队医,1993,6(5):938-9.
  • 5[5]梁秉文.经皮给药制剂[M].中国医药科技出版社,1996.55-78.
  • 6[8]储成顶,童小萍,许健健,等.Study onlocal plasma durg concentration-space-tim equation at local embedding [J ]. Asian J Drug Metabol Pharmacokinet, 2003,3 ( 1 ): 25 - 36.
  • 7Deurloo MJ, Kop W, van Tellingeno O, et al. Intratumoural administration of cisplatin in slow release devices : Ⅱ. Pharmacokinetics and intratumoural distribution [J].Cancer Chemother Pharmacol, 1991,27 ( 5 ) : 347 - 353.
  • 8Uchida A, Shinto Y, Araki N, et al. Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic [ J ]. J Orthop Res, 1992,10 (3) :440 - 445.
  • 9Meurloo MJ,Bohlken S, Kop W,et al. Intratumour administration of cisplatin in slow-release devices: Ⅰ. Tumour response and toxicity [ J ] . Cancer Chemother Pharmacol, 1990,27 ( 2 ) : 135 - 140.
  • 10Ichida T, Kato M, Hayakawa A, et al. Therapeutic effect of a CDDP-epirubicin-lipiodol emulsion on advanced hepatocellularcarcinoma [ J ] . Cancer Chemother Pharmacol, 1994,33 ( Sup pl. ) : S74 - 78.

共引文献27

同被引文献114

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部